History
Section 503A was added to the Federal Food, Drug, and Cosmetic Act by the Food and Drug Administration Modernization Act of 1997. Courts later struck down its limits on advertising. The Drug Quality and Security Act of November 27, 2013, removed those advertising provisions and left the rest of section 503A in force.
Conditions
A 503A pharmacy is exempt from FDA approval, CGMP and some labeling rules only if it meets the conditions of section 503A. The main condition is that each compounded drug is made for an identified patient, based on a valid prescription from a licensed prescriber.
The active ingredients a 503A pharmacy uses must meet set standards. In general they must be part of an FDA-approved drug, be covered by a United States Pharmacopeia monograph, or appear on the FDA 503A bulks list.
A 503A pharmacy may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug. In an April 1, 2026 update, the FDA said it does not intend to act against compounders that fill 4 or fewer prescriptions of an essentially-copy product in a calendar month. A drug is generally treated as commercially available once its shortage is resolved.
Regulation
State boards of pharmacy license and inspect 503A pharmacies and set standards for sterile compounding. The FDA can also inspect them. Unlike a 503B outsourcing facility, a 503A pharmacy does not register with the FDA as a manufacturer and does not have to follow CGMP.
Because a pharmacist must fill each order for a named patient, online weight-loss programs that offer compounded medicine pair a prescribing clinician with a 503A pharmacy that ships to the patient. See telehealth prescribing.
GLP-1 medicines
After the FDA declared the shortages resolved, 503A pharmacies had until February 18, 2025 (tirzepatide) and April 22, 2025 (semaglutide) to stop making copies that relied on the shortage list. A 503A pharmacy can still prepare a GLP-1 medicine that differs from the approved product for a patient when the prescriber documents a clinical need, such as a different strength or an added ingredient. Programs are compared on the compounded vs brand page.
Timeline
- 1997Section 503A added by the FDA Modernization Act.
- November 27, 2013Drug Quality and Security Act removes 503A advertising limits.
- February 18, 2025End of 503A shortage-based compounding of tirzepatide.
- April 22, 2025End of 503A shortage-based compounding of semaglutide.
Compare compounded and brand programs
See also
References
- FDA: Human drug compounding laws. fda.gov
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). fda.gov
- FDA: Human drug compounding. fda.gov
Last updated . Category: Pharmacy & compounding. Browse all 38 WikiTelehealth entries.